Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
APTOF logo APTOF
Upturn stock ratingUpturn stock rating
APTOF logo

DMD Digital Health Connections Group Inc (APTOF)

Upturn stock ratingUpturn stock rating
$1.25
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: APTOF (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $12.5

1 Year Target Price $12.5

Analysts Price Target For last 52 week
$12.5 Target price
52w Low $0.64
Current$1.25
52w High $15

Analysis of Past Performance

Type Stock
Historic Profit 0%
Avg. Invested days 0
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 3.34M USD
Price to earnings Ratio -
1Y Target Price 12.5
Price to earnings Ratio -
1Y Target Price 12.5
Volume (30-day avg) 1
Beta 1.02
52 Weeks Range 0.64 - 15.00
Updated Date 08/15/2025
52 Weeks Range 0.64 - 15.00
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -7.85

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -162.74%
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value 14013966
Price to Sales(TTM) -
Enterprise Value 14013966
Price to Sales(TTM) -
Enterprise Value to Revenue 0.9
Enterprise Value to EBITDA 0.05
Shares Outstanding 2552430
Shares Floating 2035664
Shares Outstanding 2552430
Shares Floating 2035664
Percent Insiders 20.25
Percent Institutions 6.79

ai summary icon Upturn AI SWOT

DMD Digital Health Connections Group Inc

stock logo

Company Overview

overview logo History and Background

It is not possible to provide the specific history of DMD Digital Health Connections Group Inc as that information is not readily available. This company is not publicly traded and the requested information is not in general public circulation.

business area logo Core Business Areas

leadership logo Leadership and Structure

It is not possible to provide the Leadership and Structure of DMD Digital Health Connections Group Inc as that information is not readily available. This company is not publicly traded and the requested information is not in general public circulation.

Top Products and Market Share

overview logo Key Offerings

Market Dynamics

industry overview logo Industry Overview

Because DMD Digital Health Connections Group Inc is not publicly traded or tracked, industry information cannot be included.

Positioning

Because DMD Digital Health Connections Group Inc is not publicly traded or tracked, position information cannot be included.

Total Addressable Market (TAM)

It is not possible to determine the TAM without more information regarding the products, business segment, and market reach of the company.

Upturn SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

Competitors and Market Share

competitor logo Key Competitors

Competitive Landscape

Competitive landscape information is not publicly available.

Growth Trajectory and Initiatives

Historical Growth: Growth information for this company is not publicly available.

Future Projections: Growth information for this company is not publicly available.

Recent Initiatives: Information on recent initiatives for this company is not publicly available.

Summary

DMD Digital Health Connections Group Inc's financial information is not readily available since it is not publicly traded. Therefore, a comprehensive analysis is not possible. Determining the company's strengths, weaknesses, opportunities, and threats (SWOT analysis) and future prospects is not possible without this data. To perform a proper assessment, proprietary financial data would need to be obtained.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Unable to obtain data for requested company

Disclaimers:

The information provided is based on the limited data available. No opinion on investment worthiness is provided as the data set is incomplete. Always conduct thorough research and seek professional advice before making investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About DMD Digital Health Connections Group Inc

Exchange NASDAQ
Headquaters Toronto, ON, Canada
IPO Launch date 2014-10-23
Chairman, President & CEO Dr. William G. Rice Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 13
Full time employees 13

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.